Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 6/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 6/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 6/20 | 1.00 |
| ▸ | HTR1A | P08908 | 7/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 4/20 | 0.48 |
| ▸ | HTR2A | P28223 | 3/20 | 0.48 |
| ▸ | HTR7 | P34969 | 3/20 | 0.48 |
| ▸ | HTR6 | P50406 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5459957 | 0.95 | ADRA1D (0.91) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| Fumaric Acid SCHEMBL5459952 | 0.95 | ADRA1D (0.91) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9200004 | 0.95 | ADRA1A (0.90) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9194060 | 0.94 | ADRA1A (0.89) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| Hydrochloric Acid SCHEMBL9316958 | 0.94 | ADRA1A (0.88) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL9317007 | 0.93 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9193925 | 0.93 | ADRA1D (0.87) | ADRA1DADRA1AADRA1BHTR1ALMNA | |
| SCHEMBL9201007 | 0.90 | ADRA1A (0.82) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL9199195 | 0.90 | ADRA1D (0.81) | ADRA1DADRA1AADRA1BHTR1ADRD2 | |
| SCHEMBL9197544 | 0.89 | ADRA1D (0.80) | ADRA1DADRA1AADRA1BHTR1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | claimed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172240-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | HARROW IP, LLC (US) | 2023-09-14 | — | — | WO | claimed |
| JP-2007509896-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682183-A2 | PHARMACEUTICAL COMPOSITION, CONTAINING A BETA-3-ADRENOCEPTOR AGONIST AND AN ALPHA ANTAGONIST AND/OR A 5-ALPHA-REDUCTASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-26 | — | — | EP | claimed |
| WO-2005042021-A2 | PHARMACEUTICAL COMPOSITION, CONTAINING A BETA-3-ADRENOCEPTOR AGONIST AND AN ALPHA ANTAGONIST AND/OR A 5-ALPHA-REDUCTASE INHIBITOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-05-12 | — | — | WO | claimed |
| EP-0435749-B1 | Derivatives of 2-aminopyrimidine-4-carboxamide, their preparation and therapeutic use | SYNTHELABO (FR) | 1996-01-10 | — | — | EP | claimed |
| US-5164397-A | Hypotensive | SYNTHELABO (FR) | 1992-11-17 | — | — | US | claimed |
| US-20250186415-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2025-06-12 | — | — | US | disclosed |
| US-20250041211-A1 | OPHTHALMIC PREPARATION AND APPLICATION THEREOF IN TREATMENT OF PRESBYOPIA | Eye Hospital, Wenzhou Medical University (CN) | 2025-02-06 | — | — | US | disclosed |
| EP-4489746-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-4489858-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | Harrow IP, LLC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-20240423970-A1 | EXTENDED-RELEASE PHARMACEUTICAL COMPOSITIONS FOR TREATING EYE CONDITIONS | FIFTH THIRD BANK, NATIONAL ASSOCIATION, AS AGENT | 2024-12-26 | — | — | US | disclosed |
| US-12102628-B2 | Composition and methods for the treatment of myopia | Seinda Pharmaceutical Guangzhou Corporation | 2024-10-01 | — | — | US | disclosed |
| EP-0520883-B1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1995-07-12 | — | — | EP | disclosed |
| EP-0577470-B1 | 2-Amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]amino]alkyl]-pyrimidine-4-carboxamide derivates, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1995-05-24 | — | — | EP | disclosed |
| US-5330985-A | Adrenergic blocking agents; urogenital disorders | SYNTHELABO (FR) | 1994-07-19 | — | — | US | disclosed |
| EP-0577470-A1 | 2-Amino-N-[[[4-(aminocarbonyl)pyrimidin-2-yl]amino]alkyl]-pyrimidine-4-carboxamide derivates, their preparation and their use in therapeutics | SYNTHELABO (FR) | 1994-01-05 | — | — | EP | disclosed |
| US-5244894-A | Treating disorders involving hyperactivity of the alpha 1-adrenergic system in lower urinary tract | SYNTHELABO | 1993-09-14 | — | — | US | disclosed |
| EP-0520883-A1 | 2-Aminopyrimidin-4-carboxamide derivatives, their preparation and their use in therapy | SYNTHELABO (FR) | 1992-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12102628-B2 | Composition and methods for the treatment of myopia | CHRM3, CHRM2, MYOC | ADRA1D 99/4885ADRA1A 74/4885ADRA1B 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.